# US 10,307,393 B2 · Application of naringenin and naringin in tumor radiotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,393 B2
- Document ID: US10307393B2
- Status: Granted
- Kind: B2
- Application number: 15/743,288
- Filed: 2016-08-25
- Published: 2018-07-19
- Granted: 2019-06-04
- Earliest claimed: 2015-07-10
- Assignees: Institute of Biophysics, Chinese Academy of Sciences; Topfond Pharmaceutical Co., Ltd.
- Applicants: Institute of Biophysics Chinese Academy of Sciences
- Inventors: Wei Liang; Chun Ling Zhang; Wen Feng Zeng; Chao Zhang; Luo Yang Wang
- Web page: https://patentgrep.com/patent/US10307393B2

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present invention provides applications of a small molecular flavonoid compound in preparing a medication for sensitizing/synergizing tumor radiation therapy as well as reducing radioactive damage. The small molecular flavonoid compound can be naringenin, hesperetin, luteolin and apigenin, etc. The medication contains a small molecular flavonoid compound and a plurality of conventional pharmaceutical additives; wherein the small molecular flavonoid compound is an active ingredient.

## Claims

### Claim 1

A method of sensitizing tumor radiotherapy as well as reducing radiation-induced toxicity, comprising the steps of:
(1) administering orally an effective amount of medication before an irradiation;
(2) conducting the irradiation;
(3) administering orally the effective amount of the medication after the irradiation;
wherein the medication comprises a small molecular flavonoid compound selected from the group consisting of naringenin, hesperetin, luteolin and apigenin.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the tumor radiotherapy is a clinically applicable radiation therapy method, consisting of:
(1) external or internal radiation therapy;
(2) stereotactic radiation therapy;
(3) direct ionizing radiation therapy or indirect ionizing radiation therapy;
(4) radiation therapy using X-ray therapy apparatus, medical accelerator or radioactive nuclide.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the tumor is a thoracic tumor.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the radiation-induced toxicity is tissue inflammation or tissue fibrosis caused by radiation.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the radiation-induced toxicity is radiation-induced lung injury consisting of radiation pneumonitis in the early stage of radiotherapy and radiation pulmonary fibrosis in the late stage of radiotherapy.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the small molecular flavonoid compound is naringenin or naringin.

### Claim 7 (depends on 3)

The method according to claim 3, wherein the thoracic tumor is a lung tumor, an esophageal tumor, a breast tumor or a mediastinal tumor.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the tumor is a thoracic tumor.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the radiation-induced toxicity is tissue inflammation or tissue fibrosis caused by radiation.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the radiation-induced toxicity is radiation-induced lung injury including radiation pneumonitis in the early stage of radiotherapy and radiation pulmonary fibrosis in the late stage of radiotherapy.
